Table 1

 Baseline characteristics of the study population

VariablesCA125 (U/ml)Omnibus p valuep Value for trend
Q1 (4.6–25.1) (n = 133)Q2 (25.3–60.3) (n = 132)Q3 (61.2–141.5) (n = 132)Q4 (141.7–1169.5) (n = 132)
ADHF, acute decompensated heart failure; AHF, acute heart failure; CA125, carbohydrate antigen 125; COPD, chronic obstructive pulmonary disease; LAD, left atrial diameter; LVDD, left ventricular diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAD, peripheral artery disease; po2, arterial oxygen partial pressure; pco2, arterial carbon dioxide partial pressure.
Values are presented as mean (SD), unless otherwise specified; categorical variables are presented as percentages.
*NYHA functional class measured under clinicaly stable conditions, before the index admission.
†Variable presented as the median (interquartile range).
Demographic and medical history
    Age, years73 (10)75 (10)73 (10)72 (11)0.1230.250
    Women, %63 (47.4)52 (39.4)66 (50.0)68 (51.5)0.2010.239
    Hypertension, %104 (78.2)106 (80.3)97 (73.5)83 (62.9)0.0060.002
    Dyslipidaemia, %46 (34.6)51 (38.6)38 (28.8)29 (22.0)0.0210.008
    Current smoker, %16 (12.1)11 (8.3)13 (9.9)13 (9.9)0.7840.651
    Diabetes mellitus, %42 (31.6)58 (43.9)49 (37.1)55 (41.7)0.1720.214
    Ischaemic heart disease, %45 (33.8)57 (43.2)51 (38.6)49 (37.1)0.4690.775
    Valvular heart disease, %38 (28.6)26 (19.7)41 (31.1)35 (26.5)0.1840.765
    Previous hospitalisation for AHF, %63 (47.4)52 (39.7)55 (41.7)57 (43.2)0.6330.579
    ADHF, %76 (57.1)85 (64.3)97 (73.4)105 (79)<0.001<0.001
    Cardiogenic shock, %3 (2.3)5 (3.8)7 (5.3)10 (7.5)0.2910.049
    Acute pulmonary oedema, %35 (26.3)29 (22)18 (13.6)9 (6.8)<0.001<0.001
    Hypertensive AHF, %18 (13.5)12 (9.1)9 (6.8)8 (6.1)0.1350.026
    NYHA class III/IV, %*18 (13.5)24 (18.3)30 (22.7)46 (34.9)<0.001<0.001
    COPD, %29 (21.8)22 (16.7)18 (13.6)27 (20.5)0.2990.634
    Stroke, %10 (7.5)10 (7.6)19 (14.4)15 (11.4)0.1900.120
    PAD, %13 (9.8)11 (8.3)10 (7.6)9 (6.8)0.8380.365
    Radiological pleural effusion, %19 (14.3)45 (34.4)67 (50.8)92 (69.7)<0.001<0.001
    Peripheral oedema, %51 (38.4)62 (47.3)84 (63.6)90 (68.2)<0.001<0.001
    Previous use of diuretics, %84 (65.1)85 (65.9)88 (66.7)95 (72.0)0.6310.244
Vital signs
    Heart rate, bpm†106 (29)100 (29)103 (28)98 (28)0.1630.104
    Systolic blood pressure, mm Hg†159 (38)156 (34)149 (35)144 (32)0.002<0.001
    Diastolic blood pressure, mm Hg†86 (21)88 (20)81 (18)81 (18)0.0030.004
ECG
    Atrial fibrillation, %43 (32.3)50 (37.9)62 (47.3)66 (50.0)0.0120.001
    QRS>120 ms, %34 (28.6)36 (32.1)24 (21.1)29 (25.4)0.2780.271
Laboratory
    Haemoglobin, g/dl13.2 (1.8)12.6 (1.9)12.3 (1.7)13.1 (1.8)<0.0010.487
    Serum creatinine, mg/dl†1.2 (0.4)1.2 (0.5)1.2 (0.5)1.3 (0.6)0.1170.123
    Uric acid, mg/dl7.5 (2.2)7.6 (2.5)8.1 (2.4)8.8 (2.9)<0.001<0.001
    Sodium, meq/l140 (4)139 (5)139 (4)139 (5)0.4670.202
    Troponin I >0.2 ng/ml, %42 (32.8)39 (31.0)35 (28.0)35 (27.8)0.7840.321
    pH†7.38 (0.14)7.40 (0.12)7.42 (0.10)7.43 (0.06)<0.001<0.001
    po2, mm Hg†57 (20)59 (14)59 (20)60 (14)0.3520.103
    pco2, mm Hg†43 (13)39 (14)38 (12)38 (10)<0.001<0.001
Echocardiography
    LVEF⩽45%45 (33.8)49 (37.1)49 (37.1)67 (50.8)0.0250.008
    LAD, mm42 (8)43 (8)46 (9)47 (7)<0.001<0.001
    LVDD, mm57 (10)56 (11)55 (9)56 (10)0.7170.927